Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of mannose-binding lectin polymorphisms on lung function in primary ciliary dyskinesia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lung clearance index for early detection of pulmonary complications after allo-HSCT in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Tidal breath eNO measurements in a cohort of unsedated hospitalized neonates-A method validation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased risk of sudden death in untreated Primary Carnitine Deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Biofilms of Mycobacterium abscessus complex can be sensitized to antibiotics by disaggregation and oxygenation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Ciprofloxacin (CIP) is frequently used when treating cystic fibrose (CF) patients with intermittent Pseudomonas aeruginosa (P. aeruginosa) lung colonization. However, approximately 20% of the patients progress to chronic infection despite early intervention. The aim of this study, was to investigate the pharmacokinetics of CIP, to evaluate if CYP3A4-related metabolism is involved and to find the optimal dose needed to eradicate intermittently colonizing bacteria in the lungs of CF patients. Methods An open-label, prospective pharmacokinetic study was performed. Twenty-two adult CF-patients were each given 500 mg CIP orally. One blood sample was taken at t = 0, and the following 12 hr, nine blood samples were collected. The optimal dose and interval was then calculated by Monte Carlo simulation. CYP3A4-activity was mesured using the Erythromycin Breath Test (ERMBT). Results A 14-fold variation in AUC for the 500 mg CIP (median 473.5 µg/ml × min), and a 30-fold variation in Cmax for CIP (median 2 µg/ml) was found. For CYP3A4-activity the variation was 8-fold. No correlation was found between the CYP3A4-activity and CIP-concentrations. The probability of eradicating intermittent P. aeruginosa colonization in the lungs of CF patients was found to be 57% (3 doses/day), when 500 mg CIP was given. It was calculated to be 89% (2 doses/day) and 94% (3 doses/day), respectivly if 750 mg CIP had been given. Conclusion A large pharmacokinetic difference of CIP in CF patiens was found, not explained by CYP3A4 variation. CIP should be given at 750 mg two or three times daily to adult CF patients with intermittently colonization. Pediatr Pulmonol. 2017;52:319-323. © 2016 Wiley Periodicals, Inc.

Original languageEnglish
JournalPediatric Pulmonology
Volume52
Issue number3
Pages (from-to)319-323
Number of pages5
ISSN8755-6863
DOIs
Publication statusPublished - Mar 2017

    Research areas

  • Journal Article

ID: 49928524